A Swedish company specializing in the development of treatments against Alzheimer's has announced that it has recruited the first patient in its phase 1b clinical study aimed at testing a first vaccine against the disease.
A potential vaccine
Alzinova AB, a Swedish biopharmaceutical company, will soon offer its first Phase 1b clinical trial for an Alzheimer's disease vaccine called ALZ-101. The researchers have just recruited their first patient. A total of twenty-six patients will be included in the study. Participants will receive four doses of ALZ-101 or a placebo. The study looked at two different strengths of ALZ-101 for about 20 weeks. The first data is expected in the second half of 2023.
The vaccine contains antibodies that the researchers say will directly target neurotoxic β-amyloid oligomers. The joint presence of β-amyloid aggregates and tau proteins are indeed the characteristic signs of Alzheimer's disease. Together, these two conditions gradually promote neuronal degeneration in patients. The stated goal of this vaccine will be to prevent these proteins from building up in the brain.
“It is very important that ALZ-101 has now entered clinical trials in an area where the unmet medical needs are so enormous. We look forward to further development of this treatment with the long-term goal of treating and preventing the onset and progression of this devastating disease, "said Kristina Torfgård, CEO of Alzinova AB.
A first step
It should be remembered that phase 1 trials like this one are being carried out initially to assess the safety and dosage of the drug or experimental vaccine. This particular trial will also seek to assess the immune response induced by the vaccine, as well as a number of biomarkers associated with Alzheimer's disease.
The clinical trial will be conducted in Finland by Alzinova's partner Clinical Research Services Turku (CRST). The biomarker analysis will be carried out in a research collaboration with Sahlgrenska University Hospital in Gothenburg.
Remember that last January, the American laboratory Eli Lilly announced that it had completed phase II of a clinical trial for a promising new drug: Donanemab. Two years ago, another clinical trial also alleviated the cognitive deficit induced by Alzheimer's disease by propagating electromagnetic waves through the skulls of several patients.
According to the World Health Organization (WHO), around fifty million people worldwide are now affected by the disease. There are also around ten million new cases each year.
Commentaires
Enregistrer un commentaire